Atypical Antipsychotic Articles

Med Shadow Interview Part 2: Treating Bipolar Disorder

Thursday, January 30th, 2014

Please check out Suelain Moy’s excellent interview of Dr. Fink, “Treating Bipolar Disorder: A Q & A with Dr. Candida Fink, Part 2.” Dr. Fink’s answers cover medication, therapy, self-help, and the benefits of having a strong support network. After reading the interview, please return here and let us know what you think.


Antipsychotics More Effective for Treating Acute Mania

Thursday, August 25th, 2011

A study published last week entitled “Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis” (Cipriani et al The Lancet 17 Aug 2011) reviewed many previous trials of medications for mania. It looked at results for any of the following medications: Aripiprazole (Abilify) , asenapine (Saphris), carbamazepine (Tegretol) , valproate (Depakote) , gabapentin (Neurontin), haloperidol (Haldol), Lamotrigine (Lamictal), lithium, Olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal) , topiramate (Topamax), and Ziprasidone (Geodon).


Study Suggests Ziprasidone Less Effective in Treating Acute Mania in Patients with Obesity

Friday, May 27th, 2011

At a recent meeting of the American Psychiatric Association, researchers presented a study suggesting that ziprasidone (Geodon) was less effective in treating acute mania in people with obesity or hyperglycemia (very high blood sugar level). The study was funded by Pfizer, which makes Geodon, and was done by looking at pooled data from previous studies performed by Pfizer looking at this medication’s effectiveness.

The lead author of the study, Roger S. McIntyre, Associate Professor of Psychiatry and Pharmacology at the University of Toronto, indicated that while the findings could be related to a need for higher doses in people with higher body mass indexes, it could also be that these differences in body mass and blood sugar could reduce the effectiveness of the drug at any dose. While this type of study is apparently uncommon in psychiatric research, it is actually quite important in helping us understand patterns of effectiveness in various medications used to treat bipolar disorder.


Evidence for Abilify (Aripiprazole) in Maintenance of Bipolar Disorder Questioned

Friday, May 6th, 2011

Abilify (aripiprazole) is an atypical antipsychotic medication commonly used to treat schizophrenia and acute mania. In 2005, the Food and Drug Administration (FDA) approved its use in the maintenance treatment of bipolar disorder – to prevent the recurrence of mood episodes. Unfortunately, evidence proving the effectiveness of Abilify as a maintenance medication for bipolar disorder is scarce and questionable.

Exposing the Truth

An article published this week in the open access journal PLoS Medicine (Tsai et al) looks critically at the scientific evidence that supports such widespread use of this medicine for maintenance treatment of bipolar disorder.


Long-Term Antipsychotic Use May Reduce Brain Volume

Tuesday, March 22nd, 2011

brain volume loss and antipsychoticsUntil recently, doctors and researchers had believed that brain volume loss in schizophrenia was caused primarily by the disease itself. One recent study, however, questions this long-held belief and identifies antipsychotics, the medications most commonly used to treat schizophrenia, as the more likely culprits.

With the increased long-term use of antipsychotics to treat schizophrenia and other forms of mental illness, especially bipolar mania, it’s important to determine whether the illness or the medication (or both) contribute to the potential loss of brain volume.

In an article published in the Archives of General Psychiatry (February, 2011) entitled “Long-term Antipsychotic Treatment and Brain Volumes,” Beng-Choon Ho, MRCPsych, et al. conclude the following:


FDA Update on the Use of Antipsychotics During Pregnancy

Wednesday, February 23rd, 2011

pregnancy and antipsychotic drugs

The U.S. Food and Drug Administration (FDA) is informing healthcare professionals that it has updated the Pregnancy section of drug labels for the entire class of antipsychotic drugs. The new drug labels now contain more and consistent information about the potential risk for abnormal muscle movements (extrapyramidal signs or EPS) and withdrawal symptoms in newborns whose mothers were treated with these drugs during the third trimester of pregnancy.

For details, see http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm

Important: Do not stop taking your antipsychotic medication if you become pregnant. Consult your healthcare professional before making any changes to your medication. Abruptly stopping antipsychotic medication can cause significant complications in your treatment.

Photo by Frank de Kleine, available under a Creative Commons attribution license.


Bipolar Disorder Medication Spotlight: Saphris

Thursday, September 9th, 2010

Genetic Engineering & Biotechnology News recently ran a brief article entitled “EU Sanctions Merck & Co.’s Sublingual Bipolar Disorder Drug Sycrest.” Sycrest was first approved in the U.S. in 2009 where Merck markets it as Saphris. Sycrest/Saphris is a “sublingual asenapine drug for treating moderate to severe manic episodes in adult patients with bipolar I disorder” and for treating schizophrenia. When used in treating bipolar disorder mania, it is most effective when used with other anti-manic medications, including lithium and Depakote.

Saphris/asenapine is the newest member of the class of drugs called atypical antipsychotics. It works in the same general manner – affecting primarily dopamine receptors. It also carries the same potential risks that we describe in our initial post on atypical antipsychotics. It is approved for use in schizophrenia and Bipolar I disorder for acute mania. It comes in a sublingual form (under the tongue), which some patients prefer, but which many people don’t like.


Bipolar Disorder Medication Spotlight: Clozaril (Clozapine)

Friday, January 23rd, 2009

With this post, we continue our biweekly series on medications used to treat bipolar disorder and related symptoms. Over the past several weeks, we covered five commonly used atypical antipsychotics, including Zyprexa (olanzapine) and Seroquel (quetiapine). Because the Zyprexa post contains a great deal of information that applies to the atypical antipsychotics as a group, we encourage you to read it first.


Bipolar Disorder Medication Spotlight: Abilify (Aripiprazole)

Friday, January 9th, 2009

With this post, we continue our biweekly series on medications used to treat bipolar disorder and related symptoms. Over the past several weeks, we covered four commonly used atypical antipsychotics, including Zyprexa (olanzapine) and Seroquel (quetiapine). Because the Zyprexa post contains a great deal of information that applies to the atypical antipsychotics as a group, we encourage you to read it first.


Bipolar Disorder Medication Spotlight: Geodon (Ziprasidone)

Friday, December 19th, 2008

With this post, we continue our biweekly series on medications used to treat bipolar disorder and related symptoms. Over the past couple weeks, we covered three commonly used atypical antipsychoticsZyprexa (olanzapine), Risperdal (risperidone), and Seroquel (quetiapine). Because the Zyprexa post contains a great deal of information that applies to the atypical antipsychotics as a group, we encourage you to read it first.


Bipolar Beat


Subscribe to this Blog:
Feed

Bipolar
Disorder



Archives





Candida Fink, M.D. and Joe Kraynak are authors of
Bipolar Disorder for Dummies.


Best of the Web - Blog 2008

Subscribe to this Blog: Feed

Recent Comments
  • T: what’s best is to ask HER! its an illness not a retardation… just dont ask her while she is in an...
  • B: Absolutely. Trouble is, the Pharma companies probably own shares in the food companies we purchase from when the...
  • B: Like many contributors to this discussion, I thought I was very much alone in this weight gain. I gained about 15...
  • candice: I take lexapro 10mg once a day. I have been diagnosed with major depressive disorder with psychotic...
  • Victoria: Hello Jil – what you wrote resonates so true with me. I grew up in constant fear because Mum was...
Find a Therapist
Enter ZIP or postal code



Users Online: 12240
Join Us Now!